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Abstract
Introduction: In vitamin K antagonist (VKA)-treated patients with severe hemorrhage, guidelines recommend prompt
VKA reversal with prothrombin complex concentrate (PCC) and vitamin K. The aim of this observational cohort study was
to evaluate the impact of guideline concordant administration of PCC and vitamin K on seven-day mortality.
Methods: Data from consecutive patients treated with PCC were prospectively collected in 44 emergency departments.
Type of hemorrhage, coagulation parameters, type of treatment and seven-day mortality mortality were recorded.
Guideline-concordant administration of PCC and vitamin K (GC-PCC-K) were defined by at least 20 IU/kg factor
IX equivalent PCC and at least 5 mg of vitamin K performed within a predefined time frame of eight hours after
admission. Multivariate analysis was used to assess the effect of appropriate reversal on seven-day mortality in all
patients and in those with intracranial hemorrhage (ICH).
Results: Data from 822 VKA-treated patients with severe hemorrhage were collected over 14 months. Bleeding was
gastrointestinal (32%), intracranial (32%), muscular (13%), and “other” (23%). In the whole cohort, seven-day mortality
was 13% and 33% in patients with ICH. GC-PCC-K was performed in 38% of all patients and 44% of ICH patients.
Multivariate analysis showed a two-fold decrease in seven-day mortality in patients with GC-PCC-K (odds ratio
(OR) = 2.15 (1.20 to 3.88); P = 0.011); this mortality reduction was also observed when only ICH was considered
(OR = 3.23 (1.53 to 6.79); P = 0.002).
Conclusions: Guideline-concordant VKA reversal with PCC and vitamin K within eight hours after admission
was associated with a significant decrease in seven-day mortality.
Introduction
In developed countries, up to 2% of the general population
receives chronic oral anticoagulation with vitamin K
antagonists (VKA) [1]. The rate of severe bleeding
complications is above 3.8% per person-year and the
associated mortality rate ranges between 10 to 60%,
especially in case of intracranial hemorrhage (ICH), in
the first week following the onset of the hemorrhage [1-4].
In case of severe hemorrhage, the two main predictors
of poor prognosis are over anticoagulation, that is, an
international normalized ratio (INR) above the therapeutic
range, and late VKA reversal (over eight hours after
presentation) [5,6].
For several decades the evidence supporting appropriate
clinical use of VKA antidotes has remained scarce [7].
In a recent randomized clinical trial, Sarode et al.
demonstrated the superiority of prothrombin complex
concentrate (PCC) versus fresh frozen plasma (FFP) to
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normalize coagulation within one hour (62.2 versus 9.6%;
P <0.05) [8]. The role of vitamin K in association with
PCC, in maintaining the normalized coagulation over six
hours has been emphasized [9]. The importance of rapid
hemorrhage control has led international guidelines to
recommend the use of PCC rather than FFP [10-12].
For complete VKA reversal, all guidelines recommend
an infusion of PCC (at least 20 IU/kg factor IX equivalent)
related to admission INR value in combination with at
least 5 mg of vitamin K to rapidly achieve a post-reversal
INR ≤1.5 and maintain a normal coagulation profile over
six hours. So as to save time, French guidelines suggest,
on the basis of a previous study, the possibility of adminis-
tering a probabilistic single-regimen dose of 25 IU/kg
of PCC and 10 mg of vitamin K as soon as a severe
hemorrhage is diagnosed [9,10]. In all situations, post-
reversal INR must be measured 30 minutes after the
infusion to evaluate the efficacy of the treatment and
make any necessary adjustments thereafter, and measured
six hours later to control the efficacy of vitamin K [10-12].
French guidelines were published in 2008 and have become
a standard of care for the management of these patients in
France [10]. Treatment time frames were not specified in
the international guidelines and the effect of early reversal
on mortality has not been studied. At a time when new
oral anticoagulant agents without specific antidotes are
emerging as promising alternatives to VKAs, it appears
important to better define the prognosis benefit of anti-
coagulant reversal in the management of patients on oral
anticoagulants with severe hemorrhage [13].
The aim of this observational study was to evaluate the
impact of guideline-concordant administration of PCC
and vitamin K (GC-PCC-K) on early mortality in VKA-
treated patients with severe hemorrhage. We tested the
hypothesis that GCA-PCC-K is associated with improved
early outcome.
Methods
Patients and procedures
This prospective observational study was conducted from
May 2009 to June 2010 in 44 emergency department
hospitals in France. The protocol was approved by the
Institutional Review Board (Comité d’évaluation de
l’éthique des projets de recherche biomédicale, CEERB,
Paris, France) on 5 June 2009. Electronic database permis-
sions were obtained from the Comité consultatif sur le
traitement de l’information en matière de recherche dans
le domaine de la santé (CCTIRS) on 15 January 2009 and
from the Commission nationale de l’informatique et des
libertés (CNIL) on 3 April 2009. Because there was no
randomization and only standard of care was performed,
the Institutional Review Board waived the need for
informed patient consent. Academic (N = 29) and general
(N = 15) hospitals located in rural or urban areas were
included. Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guidelines for report-
ing observational studies were followed [14].
In each center consecutive VKA-treated patients, aged
over 18 years with the exception of pregnant women,
with a severe hemorrhage were included in the study.
Hemorrhage was defined as severe if at least one of the
following criteria was present: 1) externalized bleeding that
cannot be stopped by applying conventional measures;
2) hemodynamic instability defined by systolic arterial
blood pressure (SAP) <90 mmHg, or signs of shock; 3)
need for an emergency procedure to stop bleeding; 4)
need for red blood cell transfusion; 5) life-threatening
bleeding or bleeding that compromises function, for
example, intracranial or intraspinal hemorrhage, intra-
ocular or retro-orbital bleeding, hemothorax, hemore-
troperitoneum, hemopericardium, deep-muscle hematoma
and/or neural compression syndrome, acute gastrointes-
tinal bleeding and hemarthrosis [10].
Hemorrhages were classified into four categories: 1)
gastrointestinal hemorrhages; 2) ICH; 3) deep-muscle
and subperitoneal hematomas; and 4) “others”, including
hemothorax, hemopericardium as well as hemorrhages for
which anticoagulant reversal is not systematically required
but may be urgently needed in case of shock or transfu-
sion (for example, epistaxis or hematuria).
The data collected were patient characteristics, medical
treatments, indication, duration and type of VKA treatment,
history of thrombotic and bleeding events, Glasgow coma
scale score (GCS), SAP, admission and post-reversal INR,
and reversal treatment data (time from admission to rever-
sal, PCC dose, vitamin K dose, surgical or radiological inter-
vention, number of transfused red blood cell units, FFP
units and platelet concentrates). GCS was divided into three
strata: GCS ≤8 (severe), 8 <GCS ≤13 (moderate), and GCS
>13 (mild). SAP was also divided into three strata: <90
mmHg (hypotension), 90 ≤ SAP ≤140 mmHg, and >140
mmHg (hypertension). Patients with an INR under 1.5 at
admission were considered as having a normal coagulation
profile. An INR between 1.5 and 4 was considered within
the therapeutic range (including in patients with mechan-
ical heart valves) and an INR >4 above the therapeutic
range. When post-reversal INR was obtained, the value and
the time from admission to the end of PCC administration
were recorded. To provide biological evidence of coagula-
tion normalization following reversal, the proportion of
patients with a post-reversal INR ≤1.5 was determined. A
four-factor PCC widely available in French hospitals was
used as Kaskadil© until September 2009 and Kanokad©
(Laboratoire Français du Biomédicament LFB, Les Ulis,
France) or Octaplex© (Octapharma, Swizerland). These prod-
ucts were a human plasma-derived four-factor PCC, includ-
ing factors II, VII, IX and X, and have undergone detergent
treatment and nanofiltration (Kanokad© and Octaplex©) for
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viral inactivation. These products also contain proteins C
and S, two natural anticoagulant vitamin K dependent fac-
tors. For these two PCC, 1 ml corresponds to 25 IU of Factor
IX. VKA reversal was considered guideline-concordant if a
PCC dose ≥20 IU/kg and a vitamin K dose ≥5 mg were ad-
ministered. Although no time frame was specified in the
guidelines, we considered treatment administration within
eight hours after hospital admission as a criterion for good
practice, based on the median time from admission to treat-
ment observed in a previous study [5,15].
The VKA reversal strategy was classified into five
levels:
– Level 0: no treatment or any treatment administered
over eight hours after admission at the hospital
– Level 1: PCC dose <20 IU/kg, vitamin K dose ≥5 mg
and time to treatment ≤8 hours
– Level 2: PCC dose ≥20 IU/kg, vitamin K dose <5 mg
and time to treatment ≤8 hours
– Level 3: PCC dose ≥20 IU/kg, vitamin K dose ≥5 mg
and time to treatment ≥4 hours and <8 hours
– Level 4: PCC dose ≥20 IU/kg, vitamin K dose ≥5 mg
and time to treatment <4 hours
GC-PCC-K was considered only for levels 3 and 4. Ad-
ministration of FFP was not considered as an appropriate
treatment according to the guidelines [10-12]. Patients
were classified automatically according to this algorithm.
If data were missing, the case was reviewed and classified
by two experts designated by the scientific committee.
In case of disagreement, a third expert was assigned to
definitely categorize the patient. Agreement between
experts was calculated (kappa score).
The primary outcome was seven-day mortality. Sec-
ondary outcome measures included thromboembolic
events and hemorrhage recurrences within seven days.
Statistical analysis
Data are presented as mean ± standard deviation (SD),
median (25th to 75th percentiles) or number (percentage).
The sample size was determined based on a preliminary
study that provided a first estimate of mortality in the
absence of appropriate reversal [16]. In the present study
the sample size was calculated at N = 750 patients in order
to allow a 80% power to detect (with a two-sided 5% α
risk) a difference in mortality corresponding to 20% in
the absence versus 12% in the presence of appropriate
reversal, estimating that approximately 30% of the studied
patients would receive appropriate reversal.
Factors associated with seven-day mortality were iden-
tified through univariate analysis (t-tests or χ2 test). A
multivariate analysis was then performed to identify
independent factors in the overall study population and
in the subgroup of patients with ICH. Variables included
in the multivariate analysis were those significant (P <0.05)
in univariate analysis and treatment appropriateness.
Calibration of the multivariate model was assessed using
the Hosmer-Lemeshow test and discrimination using
c-statistics. To perform an internal validation, we used
a bootstrapping procedure (N = 500 bootstrap samples)
to evaluate optimism of the parameters of models and
calculated the odds ratio (OR) associated with inappro-
priate treatment and its 95% confidence interval (CI).
The difference between this OR and the observed OR
in the cohort was defined as the optimism.
In view of the high mortality associated with ICH
compared with other types of hemorrhages, we also pre-
specified a subgroup analysis of patients with ICH [5].
All P-values were two-tailed and statistical significance
was set at P <0.05.
Results
The study flow chart is shown in Figure 1. A total of 833
patients were included in the study (detailed information
on patient recruitment in the participating centers is
provided in the Acknowledgment section). Eleven patients
were excluded because they did not meet the criteria for
severe hemorrhage. At Day 7, mortality was recorded for
all patients included. Therefore, the analyzed population
comprised 822 patients, including 262 (32%) patients with
ICH. The main characteristics of the whole cohort and
patients with ICH are shown in Table 1. A total of 110
patients (13%) died within seven days, including 86 ICH
patients, representing 10% of the overall population and
33% of the ICH subgroup. Deaths in the ICH subgroup
accounted for 78% of deaths in the overall population
(Table 1).
VKA reversal treatment comprised PCC in 509 patients
(62%) but only 379 (46%) received the recommended
doses (≥20 IU/kg). Only 27 patients (3%), including 2 in
the ICH subgroup, received FFP. Vitamin K was
Figure 1 Study flow chart.
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Table 1 Main characteristics of the cohort
Variable All patients (N = 822) Alive (N = 712) Dead (N = 110) P
Age (yrs) 77 ± 11 77 ± 11 80 ± 9 0.020
≤65 129 (16%) 119 (17%) 10 (9%) 0.033
66 to 75 144 (17%) 131 (18%) 13 (12%)
76 to 85 368 (45%) 310 (44%) 58 (53%)
>85 181 (22%) 152 (21%) 29 (26%)
Men 468 (57%) 408 (57%) 60 (55%) 0.587
Women 354 (43%) 304 (43%) 50 (45%)
Type of VKA treatment
Fluindione 631 (77%) 535 (75%) 96 (87%) 0.005
Acenocoumarol 99 (12%) 91 (13%) 8 (7%) 0.098
Warfarin 85 (10%) 80 (11%) 5 (5%) 0.032
Missing data 7 6 1
Indication for VKA treatment*
Atrial fibrillation 555 (68%) 470 (66%) 85 (78%) 0.013
Venous thromboembolic disease 156 (19%) 143 (20%) 13 (12%) 0.043
Prosthetic heart valve 102 (12%) 89 (13%) 13 (12%) 0.850
Others 79 (10%) 66 (9%) 13 (12%) 0.386
Duration of VKA treatment
<1 year 137 (17%) 124 (18%) 13 (13%) 0.223
1 to 5 years 236 (30%) 207 (30%) 29 (29%) 0.846
>5 years 426 (53%) 367 (52%) 59 (58%) 0.272
Missing data 23 14 9
Antiplatelet treatment** 153 (19%) 132 (19%) 21 (19%) 0.895
Aspirin 125 (15%) 107 (15%) 18 (16%) 0.688
Clopidogrel 34 (4%) 31 (4%) 3 (3%) 0.694
Missing data 1 1 0
History of severe hemorrhage** 103 (13%) 93 (13%) 10 (10%) 0.331
Missing data 10 3 7
Type of hemorrhage
Intracranial 262 (32%) 176 (25%) 86 (78%) <0.001
Gastrointestinal 264 (32%) 253 (36%) 11 (10%) <0.001
Deep-muscle hematomas 107 (13%) 103 (15%) 4 (4%) <0.001
“Other”*** 189 (23%) 180 (25%) 9 (8%) <0.001
Missing data 0 0 0
SAP (mmHg) 135 ± 36 131 ± 33 154 ± 47 <0.001
SAP
Hypertension >140 mmHg 334 (41%) 263 (37%) 71 (66%) <0.001
Normotension 90 to 140 mmHg 411 (50%) 386 (54%) 25 (23%) <0.001
Hypotension <90 mmHg 74 (9%) 62 (9%) 12 (11%) <0.001
Missing data 3 1 2
GCS 15 [15] 15 [15] 9 [4-15] <0.001
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administered in 583 patients (71%) and the recommended
dose (≥5 mg) was used in 531 patients (65%). The com-
bination of PCC (≥20 IU/kg) and vitamin K (≥5 mg),
regardless of administration time, was given to 336
patients (41%). Guideline-concordant administration of
PCC was uncertain in 15 patients (total dose of PCC
without the patient’s body weight), and two experts agreed
on 13 cases (80% agreement with a κ of 0.60). Finally,
treatment was considered concordant with guidelines in
313 patients (38%).
Admission INRs are shown in Figure 2. Post-reversal
INR values were available for 417 patients (51%); however,
they were obtained within one hour in only 61 (7%)
patients and within six hours in 225 (27%) patients.
Considering all post-reversal INR that we had collected,
the proportion of patients in which coagulation was
normalized (post-reversal INR ≤1.5) was significantly
greater with GC-PCC-K. Nobody received a complemen-
tary PCC dose in case of post-reversal INR >1.5.
In multivariate analysis, we observed that early mortality
was significantly associated with no GC-PCC-K in the
whole cohort (OR = 2.15 (1.20-3.88); P = 0.011) and ICH
patients (OR = 3.23 (1.53-6.79); P = 0.002) (Table 2). Using
bootstrapping, the OR of no guideline-concordant treat-
ment was 2.44 (1.09-5.74) in the whole cohort leading to
an optimism of 0.24.
Within the first week after admission, 10 thrombo-
embolic events with five associated deaths were recorded:
pulmonary embolism (N = 5), cerebral or coronary ische-
mic events (N = 3), venous (N = 1) and peripheral artery
thrombosis (N = 1). Hemorrhagic recurrence was observed
in 83 patients (11%) with four associated deaths, including
14 patients with two deaths in the ICH subgroup.
Discussion
This is the first study showing that GC-PCC-K (that
is, administration of recommended doses of PCC and
vitamin K) within eight hours after patient admission
for severe hemorrhage is associated with a decrease in
seven-day mortality. We found a two-fold decrease in
mortality (OR = 2.2 (1.2-3.9); P = 0.011) when guideline-
concordant treatment was performed. Mortality among
ICH patients has been reported to be approximately 20
to 30% in non-anticoagulated patients and 40 to 65% in
VKA-treated patients [5,17]. In this study, GC-PCC-K
was associated with a three-fold reduction of mortality
Table 1 Main characteristics of the cohort (Continued)
GCS
>13 684 (84%) 648 (92%) 36 (33%) <0.001
9 to 13 65 (8%) 45 (6%) 20 (19%) <0.001
≤8 64 (8%) 12 (2%) 52 (48%) <0.001
Missing data 9 7 2
Admission INR 4.7 ± 3.4 4.7 ± 3.5 4.4 ± 2.7 0.236
Normal (≤1.5) 45 (5%) 40 (6%) 5 (5%) 0.385
Therapeutic (>1.5 to 4) 394 (48%) 341 (48%) 53 (48%)
Supratherapeutic (>4) 345 (42%) 300 (42%) 45 (41%)
Missing value 38 (5%) 31 (4%) 7 (6%)
VKA reversal treatment
No guideline-concordant
Level 0 361 (44%) 299 (42%) 62 (56%) 0.06
Level 1 103 (13%) 92 (13%) 11 (10%)
Level 2 34 (4%) 32 (5%) 2 (2%)
Guideline-concordant
Level 3 90 (11%) 85 (12%) 5 (5%)
Level 4 217 (26%) 190 (27%) 27 (25%)
VKA reversal treatment
Not guideline-concordant (Levels 0 + 1 + 2) 509 (62%) 432 (61%) 77 (70%) 0.06
Guideline-concordant (Levels 3 + 4) 313 (38%) 280 (39%) 33 (30%)
Data are mean ± SD, median [25th to 75th percentiles], or number (percentage). P-values refer to comparison between alive and dead patients at Day 7.
INR, international normalized ratio; SAP, systolic arterial blood pressure; GCS, Glasgow coma scale; VKA, vitamin K antagonist.
*The sum is higher than 100% because two indications can be established for the same patient.
**Patients with no antiplatelet treatment or no history of severe hemorrhage are deducted from the presented results.
***“Other” types include hemopericardium (N = 1), hemothorax (N = 15), vascular bound (N = 4), emergency procedures (N = 126) and shock or red blood cells
transfusion for epistaxis (N = 55), hematuria (N = 34) or wound of the scalp (N = 4).
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in the ICH subgroup (OR = 3.2 (1.5 to 6.8); P = 0.002),
suggesting that recommended doses of PCC and vitamin
K administered in the first eight hours, can decrease
mortality to levels close to those observed in non-
anticoagulated ICH patients. The very low mortality rate
(4%) observed in patients with other types of severe
hemorrhage does not allow us to draw conclusions with
regard to these patients due to lack of statistical power.
Hypotension was associated with increased mortality in
the whole cohort, but this association was not observed in
ICH patients. GCS was also strongly associated with early
mortality. As a result of population ageing, the prevalence
of VKA-related hemorrhagic complications (ICH in par-
ticular) increases worldwide [1,5]. The median age of 80
years in our study is a clear reminder of this fact. However,
we did not observe a statistically significant association
between age and mortality.
Guideline-concordant treatment doses for normalization
of coagulation and a fixed time frame within which reversal
is considered useful are probably the two conditions
required to improve prognosis. To achieve a post reversion
INR ≤1.5, most pharmaceutical companies recommend a
PCC dose related to admission INR value. However, INR
is not a linear representation of the coagulation and a
dose-response curve has not been demonstrated in the
literature [18,19]. Moreover, in the absence of bedside
INR monitoring, waiting for an admission INR value
from the laboratory in bleeding patients may result in
increased blood losses and coagulation factor consumption.
Based on a previous small cohort study of VKA-treated
patients with ICH suggesting that a single-regimen dose
of PCC (administered as an intravenous bolus) is effective
in achieving a post-reversal INR ≤1.5, French guidelines
recommend, in order to save time when admission INR is
not available, the administration of a single-regimen dose
of 25 IU/kg factor IX equivalent PCC (that is, 1 mL/kg
with available four-factor PCCs) in combination with 10
mg of vitamin K [9,10]. Use of the recommended single-
regimen dose has not yet become routine practice, as
shown by the fact that only 205 patients (25%) received a
dose of 25 IU/kg in our study. Guidelines also strongly
recommend measuring the INR after reversal to control
the degree of reversal and further normalize the coagula-
tion 30 minutes after the first administration if the PCC
dose was insufficient [10]. Unfortunately, post-reversal
INR was obtained within less than one hour in only 7%
of our patients, underscoring the need for improved
guideline adherence. In our study, bedside INR monitor-
ing was never used. Adoption of this technique might help
increase the rate of post-reversal INR measurement within
one hour after treatment administration.
Time between hemorrhage onset and VKA reversal is a
key variable to be considered when evaluating treatment
efficacy. In patients with ICH, hematoma volume is crucial
for the prognosis and is known to increase during the first
day following admission [20]. Not surprisingly, it has been
shown that late reversal, over eight hours after admission,
does not modify the outcome [5]. Based on a previous
study, we chose a time frame of eight hours to define
timely treatment, which was considered realistic taking
into consideration the time needed to confirm the diagno-
sis of hemorrhage, which is not always easy, for example,
in patients with deep-muscle hematoma, gastrointestinal
hemorrhage or ICH.
Fear of thrombosis may be one of the reasons for not
performing VKA reversal, particularly in patients (6%) with
a normal initial INR (≤1.5) and a potentially high throm-
botic risk if the single-regimen approach is considered. In
severely bleeding patients with a high thromboembolic
risk, total mortality (N = 110, 13%) was mainly related
to hemorrhage, with only five deaths (0.6%) observed in
patients with a thromboembolic event [21]. This provides
All patients
(N = 822)
Admission INR
60%
50%
40%
30%
20%
10%
0%
Missing              0 to1.5               1.5 to 4                   >4
data
4.6% 5.5%
47.9%
42.0%
ICH patients
(N = 262)
Admission INR
70%
60%
50%
40%
30%
20%
10%
0%
Missing             0 to 1.5                1.5 to 4                   >4
data
5.0% 6.5%
61.8%
26.7%
A B
Figure 2 Admission INRs in the whole cohort (A) and in the ICH subgroup (B). Most patients were in the therapeutic range (INR between
1.5 and 4). ICH, intracranial hemorrhage; INR, international normalized ratio.
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a good example of the risk balance and reinforces the fact
that the priority is to organize a rapid reversal as soon as
the diagnosis of severe hemorrhage is confirmed.
Some limitations of our study deserve consideration.
First, we studied mortality within seven days as it
appears to be the period when the cause of death is a
direct consequence of hemorrhage in all situations, even
in ICH patients [22]. In a study of ICH-related mortality
in warfarin users and non-users, Huhtakangas et al.
observed a two-fold difference between death rates during
the first week after stroke onset and no further increase
after one week with parallel mortality curves [3]. We
considered that many clinical complications or medical
attitudes not related to VKA reversal could interfere with
30-day mortality in all groups. Second, we did not exclude
patients with care limitation decisions, although such
decisions are not rare in an aged population with severe
neurological insults, such as in ICH, and may also be
associated with “self-fulfilling prophecies” [23]. In an obser-
vational study conducted in emergency conditions it was
not possible to clearly identify the timing of these decisions
in relationship with VKA reversal and to precisely distin-
guish explicit and implicit decisions during this early phase.
It is interesting to consider that only 41% of patients
received the recommended doses of PCC and vitamin K
and only 38% of them did so within the first eight hours
Table 2 Multivariable analysis of early (seven-day) mortality
Variable All patients (N = 822) ICH (N = 262)
N OR (95% CI) P N OR (95% CI) P
Type of hemorrhage 822
“Other”* 189 1.0
Gastrointestinal 264 0.61 (0.22 to 1.70) NS
Deep-muscle 107 0.51 (0.14 to 1.93) NS
ICH 262 5.05 (1.97 to 12.94) <0.001
Age (years) 822 262
≤65 years 129 1.0 34 1.0
66 to 75 144 1.01 (0.35 to 2.93) NS 47 2.32 (0.57 to 9.47) NS
76 to 85 368 1.67 (0.68 to 4.10) NS 122 2.71 (0.78 to 9.34) NS
>85 181 2.21 (0.84 to 5.77) NS 59 3.79 (1.01 to 14.26) 0.049
Admission INR 822 262
≤1.5 45 1.0 17 1.0
No INR 38 0.76 (0.12 to 4.71) NS 13 1.01 (0.11 to 9.71) NS
>1.5 to 4 394 1.12 (0.33 to 3.80) NS 162 1.40 (0.32 to 6.19) NS
>4 345 1.36 (0.38 to 4.87) NS 70 1.56 (0.31 to 7.81) NS
GCS score 813 261
>13 684 1.0 149 1.0
9 to 13 65 3.67 (1.80 to 7.51) <0.001 51 4.23 (1.87 to 9.53) <.001
≤8 64 30.35 (13.43 to 68.61) <0.001 61 39.81 (15.70 to 100.91) <.001
SAP 819 262
90 to 140 mmHg 411 1.0 64 1.0
<90 mmHg 74 7.91 (3.06 to 20.44) <0.001 3 0.67 (0.01 to 33.01) NS
>140 mmHg 334 1.15 (0.58 to 2.28) NS 195 1.29 (0.55 to 3.06) NS
VKA reversal 822 262
Guideline concordant 313 1.0 0.011 116 1.0 .002
Not guideline-concordant 509 2.15 (1.20 to 3.88) 146 3.23 (1.53 to 6.79)
Hosmer–Lemeshow Goodness-of-Fit
Test: Pr >χ2 = 0.99
Hosmer–Lemeshow Goodness-of-Fit
Test: Pr >χ2 = 0.52
c-statistic = 0.89 c-statistic = 0.86
CI, confidence interval; ICH, intracranial hemorrhage; GCS, Glasgow coma scale; NS, not statistically significant; OR, odds ratio; SAP, systolic arterial blood pressure;
trt: treatment.
*“Other” types include hemopericardium (N = 1), hemothorax (N = 15), vascular bound (N = 4), emergency procedures (N = 126) and shock or red blood cell
transfusion for epistaxis (N = 55), hematuria (N = 34) or a wound of the scalp (N = 4).
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after the onset of bleeding. These results were similar to
those of a previous study [16]. A large French study, which
was performed in 33 hospitals during 2008 to 2011 showed
the same difficulties in obtaining good guideline adherence
for VKA reversal in patients with severe hemorrhage [24].
More important, in our study, only 27% of patients who
had received PCC had an INR post-reversion during the six
hours. It appears therefore necessary to promote guideline
dissemination and implementation. It would also be benefi-
cial to improve the current guidelines by including explicit
time frames for treatment administration.
Conclusion
Guideline-recommended doses of PCC and vitamin K
were associated with a reduced mortality in patients on
VKA therapy presenting with severe hemorrhage, par-
ticularly among patients with ICH in whom we observed
a three-fold decrease in mortality. VKA reversal should
be initiated within eight hours after admission. Only
38% of our patients received appropriate treatment, indi-
cating the need for improved guideline adherence.
Key messages
 In patients on VKA therapy presenting with severe
hemorrhage, international guidelines recommend, as
soon as the diagnosis is confirmed, the administration
of PCC (≥20 UI/kg) and vitamin K (≥5 mg) to
normalize coagulation (post-reversal INR ≤1.5).
 A guideline-concordant administration dose of PCC
and vitamin K administrated in the first eight hours
was associated with a two-fold decrease in seven-day
mortality overall and with a three-fold decrease in
the ICH subgroup
 The guideline-concordant reversal was performed in
38% of the patients within eight hours after admission
 Whereas pre-reversal INR is not absolutely necessary,
post-reversal INR is essential to evaluate treatment
efficacy
 The post-reversal INR target must be performed
systematically and immediately after PCC
administration
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